|
Apr 1
|
Biotech stocks slide as Marks resignation seen being negative for sector
|
|
Mar 14
|
Q4 2024 Regenxbio Inc Earnings Call
|
|
Mar 14
|
Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience
|
|
Mar 13
|
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 13
|
Regenxbio: Q4 Earnings Snapshot
|
|
Mar 13
|
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
|
|
Mar 10
|
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
|
|
Feb 20
|
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Feb 11
|
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
|
|
Feb 10
|
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 333.01%: Read This Before Placing a Bet
|
|
Sep 3
|
RegenxBio touts positive data for rare disease drug RGX-121
|
|
Sep 3
|
REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
|
|
Jul 25
|
REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
|
|
Jul 12
|
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
|
|
Jul 8
|
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
|
|
Jun 24
|
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
|
|
Jun 21
|
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
|
|
Jun 21
|
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
|
|
Jun 18
|
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
|
|
Jun 18
|
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
|